GlassScriptPhysician profile
Stephen Gerard Tiley
NPI 1245425966
$2,021.31
in general payments reported to CMS, 2019-2025
28 companies · $822 in 2025
The $822 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $14.31 · 2021: $128 · 2022: $253 · 2023: $172 · 2024: $124 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,102 · Education: $15.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,102.08 |
| Education | $15.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $350.04 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $163.01 | 2019-2023 | Lumakras |
| Adaptive Biotechnologies Corporation | $150.00 | 2025 | Clonoseq |
| Genentech USA, INC. | $139.41 | 2019-2025 | Polivy, Venclexta, Gazyva |
| Astrazeneca Pharmaceuticals LP | $138.93 | 2019-2025 | Imfinzi, Lynparza |
| Novartis Pharmaceuticals Corporation | $137.57 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $131.01 | 2019-2025 | Opdivo, Opdualag |
| Genzyme Corporation | $100.53 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.97 | 2019-2025 | |
| Celgene Corporation | $80.13 | 2019-2025 | Reblozyl |
| Astellas Pharma US INC | $71.15 | 2023-2025 | Padcev, Xtandi |
| Pfizer INC. | $53.05 | 2025 | |
| Daiichi Sankyo INC. | $49.54 | 2023-2025 | Datroway, Enhertu |
| Abbvie INC. | $40.60 | 2019 | |
| Gilead Sciences, INC. | $35.97 | 2022-2023 | Trodelvy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $34.78 | 2022 | |
| Beone Medicines USA, INC. | $34.14 | 2025 | Brukinsa |
| Eisai INC. | $32.52 | 2019-2025 | |
| Janssen Biotech, INC. | $28.32 | 2019-2024 | Rybrevant |
| G1 Therapeutics, INC. | $25.03 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $22.72 | 2025 | Libtayo |
| Tempus Ai, INC | $20.92 | 2024 | |
| Puma Biotechnology, INC. | $19.56 | 2019 | |
| Mylan Institutional INC. | $19.11 | 2021 | |
| Pharmacosmos Therapeutics INC. | $19.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.62 | 2019 | |
| Array Biopharma INC | $13.37 | 2024 | Braftovi, Mektovi, Tukysa |
| Teva Pharmaceuticals USA, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Tiley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.